ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
Filing Information
| Accession Number | 0001735276-26-000038 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 2, 2026 |
| Document | View SEC Filing |
Transactions
7
Total Shares
8,443
Total Value
$1,533,099.58
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Exercise/Conversion | 1,908 | $0.00 | $0.00 | 26,756 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Sale | 127 | $328.92 | $41,772.84 | 26,629 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Sale | 2,259 | $330.73 | $747,119.07 | 24,370 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Sale | 1,159 | $331.49 | $384,196.91 | 23,211 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Sale | 942 | $332.48 | $313,196.16 | 22,269 | Direct | โ | View Details | |
EVP Chief R&D | Common Stock | โ | Feb 27, 2026 | Sale | 140 | $334.39 | $46,814.60 | 22,129 | Direct | โ | View Details | |
EVP Chief R&D | Restricted Stock Units | Derivative | Feb 27, 2026 | Exercise/Conversion | 1,908 | $0.00 | $0.00 | 0 | Direct | โ | View Details |